Studies on the cytotoxicity of cytosine arabinoside.
D000293:Adolescent; D000328:Adult; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D001853:Bone Marrow / Q000473:pathology; D002453:Cell Cycle; D002454:Cell Differentiation; D002478:Cells, Cultured; D002999:Clone Cells / Q000473:pathology; D003114:Colony-Forming Units Assay; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004247:DNA / Q000096:biosynthesis; D004351:Drug Resistance; D005260:Female; D006098:Granulocytes / Q000473:pathology; D006207:Half-Life; D006801:Humans; D007399:Interphase; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010766:Phosphorylation; D012008:Recurrence
D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D004247:DNA